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MicroalbuminuriaAbstract Background: Serum vascular endothelial growth factor (VEGF) levels are increased in sepsis.
Purpose: To investigate the prognostic value of the serum VEGF level in critically ill septic patients
regarding the clinical course and final outcome.
Methods: A total of 40 critically ill septic patients were included in a prospective, randomized, single
center study. All patients were subjected to the measurement of VEGF levels on admission day (VEGF1)
and 48 hours later (VEGF2). CRP levels andMicroalbuminuria levels were also measured on admission.
APACHE IV and SOFA scores were calculated. Clinical outcome (duration of stay in the ICU, need for
MV, need for inotropic/vasopressor support, need for hemodialysis, and survival) was recorded.
Results: In relation tohealthy subjects, themeanVEGF1&2 levelswere significantlyhigher in the septic
patients (142 + 28.98 vs 750.5 + 380.34 and 802.07 + 292.65 ng/l; p= 0.001 and <0.001 respectively).
Septic patients who required MV, inotropic/vasopressor support and hemodialysis, and also those who
died had significantly higher VEGF1 levels compared to those who didn’t require them (p= 0.002,
0.006, 0.008 and 0.001 respectively). VEGF2 level was significantly higher only in those who required
inotropic/vasopressor support (p= 0.024). VEGF1 and 2 levels were significantly positively correlated
with CRP level, Albumin/Creatinine ratio and APACHE IV score. ROC analysis of the data indicated
a sensitivity of 85.15%and a specificity of 92.3%when aVEGF1 level of 410 ng/l was taken as a predictor
of ICU mortality.
Conclusion: The admission VEGF is a useful marker for the evaluation of septic patients.
 2016 The Egyptian College of Critical Care Physicians. Production and hosting by Elsevier B.V. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).street,
Gaber),
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The prognosis of patients is important in risk stratification and
for the efficient use of hospital resources. Predicting the out-
come of patients in the intensive care environment is of partic-
ular significance to ensure that resources are used
appropriately. Incidence of sepsis is increasing. Severe sepsis,
which occurs when sepsis progresses to involve acute organ
dysfunction, results in more than 200,000 annual fatalities,
and the number of cases is projected to increase [1].
Vascular permeability increases in response to systemic
inflammation mediated by endotoxin and various cytokines.
Macrophages and lymphocytes can produce vascular endothe-
lial growth factor (VEGF) [2,3]. The vascular permeability fac-
tor was isolated in 1983 [4]. VEGF was identified in 1989, and
in the same year, these two substances were found to be iden-
tical [5,6].
There are seven different VEGFs (VEGF-A,-B,-C,-D,-E,-F
and placental growth factor PlGF), which have different phys-
iological and biological properties. There are at least 6 VEGF-
A isoforms of different sizes (with 121,145, 165, 183, 189 and
206 amino acid residues) [7,8]. VEGFs are involved, for
instance, in wound healing, cardiovascular diseases, tumour
growth and progression, ocular neovascularization and inflam-
matory diseases such as rheumatoid arthritis. In particular,
VEGF-A acts on endothelial cells, causing vasodilatation by
induction of endothelial nitric oxide synthase [9]. VEGF-A
also has antiapoptotic effects on endothelium [10]. More
importantly, VEGF-A was found to be an important mediator
of vascular permeability [5]. Also, VEGF is a potent hypoxia-
induced mediator in the formation of new capillaries (angio-
genesis). VEGF-induced angiogenesis was also found to play
an important role in the etiology of several additional diseases
associated with abnormal angiogenesis as tumor angiogenesis
[11–13] and in wound repair [14].
A number of prognostication tools have been developed for
prediction of outcome in the critically ill septic patients, such
as scoring systems (including Acute Physiology and Chronic
Health Evaluation IV ‘‘APACHE IV” [15] and The Sequential
Organ Failure Assessment score ‘‘SOFA” [16]) and chemical
biomarkers (including CRP [17–19], procalcitonin [20],
microalbuminuria [21,22] and inflammatory cytokines as IL6
and IL8 [23]).
The aim of this work is to investigate the prognostic value
of VEGF concentrations in critically ill septic patients, and
also to compare this prognostic value of VEGF with other bio-
chemical markers for the prognosis of sepsis (CRP and
microalbuminuria) and with the APACHE IV and SOFA scor-
ing systems.
2. Patients and methods
2.1. Patients
Forty patients who had been diagnosed with sepsis and were
admitted to the Critical care department at Cairo university
hospital from September 2013 to August 2014 were enrolled
in this prospective observational single centre study. The study
protocol was approved by the ethics committee. This study did
not interfere with normal routine patient management.Inclusion criteria: (1) AgeP 18 years old (2) Informed con-
sent given by the patient or immediate relative (first degree) (3)
Sepsis (ACCP/SCCM criteria) [24]: (a) Clinically suspected
infection as per the treating physician or confirmed infection
and (b) 2 or more of the following: Temperature >38 C
(100.4F) or <36 C (96.8F), heart rate (HR) > 90/min, res-
piratory rate (RR) > 20/min or PaCO2 < 32 mmHg, White
blood cell count > 12,000/mm3 or <4000/mm3 or >10%
immature neutrophils. Severe sepsis is defined as sepsis plus
sepsis-induced organ dysfunction or tissue hypoperfusion. Sep-
tic shock is defined as sepsis-induced hypotension persisting
despite adequate fluid resuscitation. Sepsis-induced hypotension
is defined as a systolic blood pressure (SBP) <90 mmHg or
mean arterial pressure (MAP) <70 mmHg or a SBP decrease
>40 mmHg in the absence of other causes of hypotension.
Exclusion criteria included trauma, burns, acute myocardial
infarction and patients with a history of autoimmune disease
or malignancy.
Patients who were diagnosed as having sepsis at ICU
admission and did not meet any of the exclusion criteria were
included into the study on the day of ICU admission, and sub-
sequently followed up until the day of discharge or demise.
The blood samples were also collected from 10 healthy age
matched subjects as a control.
2.2. Evaluation of patients
All included patients were subjected to the following
2.2.1. Full clinical evaluation
Including a history and physical examination with a special
emphasis on vital signs (BP, HR, Temperature and RR) and
Glasgow coma scale (GCS); these were evaluated on the day
of admission and then followed up daily (every 2 h for vital
signs and once daily for GCS).
2.2.2. Laboratory investigations
 Routine Labs: CBC (complete blood count): Hemoglobin,
Hematocrit, White blood cells and platelet count, Coagula-
tion profile: PT, PC, INR and PTT, Kidney Function Tests:
Na, K, Creatinine and Urea, Liver Function Tests: ALT
(Alanine aminotransferase), AST (Aspartate aminotrans-
ferase), BIL (bilirubin) and albumin and ABGs (arterial
blood gases).
These routine Labs were withdrawn on study day 1 and
subsequently thereafter every day until ICU discharge or
demise.
 Labs specific for this study: Total VEGF (Vascular Endothe-
lial Growth Factor) [25,26]: VEGF was measured using a
double-antibody sandwich enzyme-linked immune sorbent
assay (ELISA) on the day of admission (VEGF1) and after
48 h i.e. on the morning of the third day (VEGF2). VEGF
was added to the monoclonal antibody enzyme well, which
was pre-coated with an incubated human VEGF mono-
clonal antibody. Then, VEGF antibodies labeled with biotin
were added and combined with Streptavidin-HRP to form
an immune complex, which was then incubated and washed
again to remove the uncombined enzyme. After this, a chro-
mogen solution was added, causing the color of the liquid to
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becomes yellow. Both the chroma of color and the concen-
tration of VEGF of sample were positively correlated.
CRP (C-reactive protein)[18]: Measured by ELISA on the
day of admission, which is based on the principle of a solid
phase enzyme-linked immunosorbent assay utilizing a
mouse monoclonal antibody against distinct determinants
for immobilization on the microtiter wells, and a goat
anti-CRP antibody conjugated to horseradish peroxidase
(HRP) for detection. Microalbuminuria [22]: It is generally
expressed as the urinary albumin to creatinine ratio to cor-
rect the variations in urinary flow rate. Urinary micro albu-
min was measured using the immunoturbidimetric method
and urinary creatinine through a modified kinetic Jaffe reac-
tion (Dimension RxL Max, Dade Behring Inc., U.S.A) on
the day of admission. Microalbuminuria was defined by
Albumin/Creatinine Ratio values between 30 and
299 mg/g creatinine. Albumin/Creatinine Ratio > 300 mg/g
creatinine is considered as clinical proteinuria. Albumin/
Creatinine Ratio < 30 mg/g creatinine is normal.
2.2.3. Clinical and outcome data
Length of ICU stay, final outcome of survival rates and need
for organ supportive measures (Vasopressors, MV and/or
Hemodialysis) were reported for all patients until ICU dis-
charge or demise.
2.2.4. Application scoring systems
APACHE IV score [15], which is a severity of disease classifi-
cation system, was evaluated on the day of admission. After
admission, an integer score is computed based on several mea-
surements; higher scores imply a more severe disease and a
higher risk of death. SOFA score [16] was evaluated on study
day 1 and serially every other day until ICU discharge or
demise. This score determines the extent of a person’s organ
function or rate of failure.
2.2.5. The statistics
Continuous variables were summarized using range, mean
± SD. Categorical variables were summarized using frequen-
cies and relative frequencies. A comparison of quantitative
variables between the study groups was conducted using a
Mann Whitney U test for independent samples. Accuracy
was represented using the terms sensitivity and specificity of
VEGF levels. A receiver operator characteristic (ROC) analy-
sis was used to determine the optimum cut off value for the
studied diagnostic markers. Correlation between various vari-
ables was done using a Spearman rank correlation equation
for non-normal variables. A probability value (p value) of less
than 0.05 was considered statistically significant. All statistical
calculations were done using SPSS (Statistical Package for the
Social Science; SPSS Inc., Chicago, IL, USA) version 22 for
Microsoft Windows.
3. Results
3.1. Demographic and baseline clinical data at ICU admission
Table 1.3.2. VEGF and baseline clinical characteristics
On admission, VEGF was measured in the serum of all
included patients, whereas VEGF 2 was measured only in
the serum of 29 patients (as 11 patients died during the first
48 h of ICU admission). The mean level of VEGF1 was
750.50 ± 380.34 ng/l, approximately 6 folds higher than con-
trol subjects, (142 ± 28.98 ng/l, P= 0.001). The mean VEGF
2 level was 802.07 ± 292.65 ng/l, approximately 7 folds higher
than control subjects, (P< 0.001), but there was no significant
correlation between admission VEGF and VEGF 2,
(P= 0.272). Moreover, there was no significant correlation
between plasma VEGF1 and VEGF 2 levels and age
(p= 0.258 and 0.068 respectively). Also, there was no signifi-
cant correlation between the plasma VEGF1 and VEGF 2
levels and sex (p= 0. 171 and 0.433). Also there was no signif-
icant correlation between postoperative and medical patients
(p= 0.570 and 0.229).
The elevated levels of VEGF in the studied septic patients
increased with the increasing severity of the septic condition
at ICU admission, at which point it could be seen that the
patients with a diagnosis of septic shock at ICU admission
had significantly higher plasma VEGF1 levels (911.18
± 449.86 ng/l) than those with sepsis (575 ± 212.94 ng/l,
p= 0.009). However, no significant difference was found
between plasma VEGF1 levels in patients with severe sepsis
(1043.33 ± 353.46 ng/l) and those with sepsis and septic shock
(P= 0.142 and 0.604 respectively) Table 2.
3.3. VEGF and severity of illness during ICU stay (need for
organ supportive measures)
The mean level of the VEGF1 was significantly higher in
patients who required MV (29 patients) (836.21 ± 399.85 ng/l)
than those who did not require it (11 patients) (524.56 ±
197.55 ng/l, P= 0.002), and also in those who required
inotropic/ vasopressor support (26 patients) (853.84 ±
406.55 ng/l) versus the group who did not require it
(14 patients) (565.71 ± 208.45 ng/l, P= 0.006). In addition,
higher VEGF1 level was found in those who required
hemodialysis (11 patients) (824.83 ± 407.16 ng/l) versus those
who did not require it (29 patients) (554.55 ± 204.27 ng/l,
P= 0.008). Also, the mean VEGF 2 level was significantly
higher in patients who required inotropic/ vasopressor support
(20 patients) (927.37 ± 279.64 ng/l) versus those who did not
require it (9 patients) (720 ± 169.12 ng/l, P= 0.024). On the
other hand, there were no significant differences seen in the
mean VEGF 2 level between patients who did not require
MV (6 patients) (813.33 ± 132.77 ng/l) and those who
required it (23 patients) (799.13 ± 323.97 ng/l), (P= 0.871)
and also in those who required hemodialysis (8 patients)
(737.50 ± 197.76 ng/l) and those who did not require it (21
patients) (826.67 ± 322.36 ng/l, P= 0.378).
3.4. VEGF and length of ICU stay, CRP, microalbuminuria,
APACHE-IV and SOFA
An insignificant correlation was found between VEGF1 level
and the length of ICU stay, (r = 0.015, p = 0.927); however,
a significant positive correlation was found between VEGF 2
level and the length of ICU stay (r= 0.448, p = 0.015).
Table 1 Demographic and clinical data of patients entered
into the study.
Variables Values
Age (years) Mean ± SD
(Range)
69.25 ± 8.79
(53–82)
Male: Female sex (Ratio) 19: 21 (0.904)
Clinical history
Hypertension N(%) 12 (30%)
Diabetes mellitus N(%) 18 (45%)
Medical: Post-operative cases (Ratio) 11: 29 (0.379)
Etiology of sepsis
Chest Infection N(%) 14 (35%)
Urinary tract infection N(%) 10 (25%)
Soft tissue infection N(%) 10 (25%)
Intra abdominal sepsis N(%) 3 (7.5%)
CNS infection N(%) 3 (7.5%)
Severity of sepsis at ICU admission
Sepsis N(%) 20 (50%)
Severe sepsis N(%) 3 (7.5%)
Septic shock N(%) 17 (42.5%)
Baseline hemodynamic
Heart rate (beat/min) Mean ± SD 107.3 ± 28.43
Respiratory rate (breath/min) Mean ± SD 23.7 ± 6.61
Temperature (C) Mean ± SD 37.69 ± 0.80
Systolic blood pressure
(mmHg)
Mean ± SD 97.5 ± 17.20
Diastolic blood pressure
(mmHg)
Mean ± SD 61.57 ± 10.25
Mean blood pressure (mmHg) Mean ± SD 73.45 ± 12.32
Central venous pressure
(CmH2O)
Mean ± SD 8 ± 6.65
GCS Mean ± SD 13.9 ± 1.13
Baseline Laboratory investigations
Hemoglobin (gm/dl) Mean ± SD 10.25 ± 1.76
Hematocrite (%) Mean ± SD 30.60 ± 4.42
Leucocytes (cell/mm3) Mean ± SD 13.46 ± 7.75
aPTT (s) Mean ± SD 36.6 ± 8.29
INR Mean ± SD 1.54 ± 0.57
ALT (U/L) Mean ± SD 63.15 ± 37.40
AST (U/L) Mean ± SD 57.37 ± 39.52
Total bilirubin (mg/dl) Mean ± SD 1.72 ± 1.44
Albumin (g/dl) Mean ± SD 2.29 ± 0.39
Blood urea (mg/dl) Mean ± SD 121.05 ± 71.88
Serum creatinine (mg/dl) Mean ± SD 2.34 ± 1.36
Sodium (mEq/L) Mean ± SD 134.15 ± 6.96
Potassium (mEq/L) Mean ± SD 3.88 ± 0.79
Clinical coarse and outcome
Need for mechanical
ventilation
N(%) 29 (72.5%)
Duration of mechanical
ventilation (day)
Mean ± SD 4.47 ± 3.28
Need for
inotropic/vasopressor support
N(%) 26 (65%)
Need for hemodialysis N(%) 11 (27.5%)
Duration of ICU stay (day) Mean ± SD 3.53 ± 1.81
Mortality N(%) 24 (60%)
N: number; aPTT: activated partial thromboplastin time; AST:
alanine aminotransferase, AST: aspartate aminotransferase; GLS:
Glasgow coma scale
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CRP level at ICU admission (r = 0.475, p = 0.002), with
microalbuminuria level at ICU admission (r = 0.623,
p< 0.001) and also with APACHE IV score (r = 0.397,
p< 0.001), whereas this was not the case with the SOFA score
(r = 0.153, p= 0.345). Table 3 and 4.
3.5. VEGF and final outcome
The ICU mortality rate was 60% (24 of 40 patients). The mean
level of VEGF1 in non-survivors was 893.33 ± 408.26 ng/l,
which was significantly higher than that in survivors (542.50
± 207.54 ng/l, P = 0.001). However, no significant difference
was found between the VEGF 2 level in non survivors
(792.22 ± 356.71 ng/l) and survivors (889.09 ± 37 ng/l),
(P = 0.268).
3.6. Prognostic ability of VEGF
The receiver operator characteristic (ROC) curve was calcu-
lated for the use of VEGF1 level as a predictor of ICU mortal-
ity. The area under the ROC (AUROC) curve for VEGF1 to
predict ICU mortality was 0.746 (95% confidence interval,
0.594–0.898, p= 0.009). The optimal cutoff value for VEGF1
to predict ICU mortality was 410 ng/l. This cutoff value gave a
sensitivity of 85.15% and a specificity of 92.3% for ICU
mortality.
AUROC curves were also calculated for CRP, Microalbu-
minuria, APACHE IV and SOFA scores in the prediction of
ICU mortality. The AUROC curve for CRP was 0.462 (95%
CI, 0.281–0.643); the best cut-off value to predict ICU mortal-
ity was 25 mg/L with a sensitivity of 56.5% and a specificity of
35.3%. The AUROC curve for Microalbuminuria was 0.382
(95%CI, 0.207–0.757); the optimal cut-off value was 357 mg/g
with a sensitivity of 50% and a specificity of 21.4%. The
AUROC curve for SOFA score was 0798. (95%CI, 0.633–
0.963); the best cutoff score was 9 with a sensitivity of
81.8% and a specificity of 66.7%. The AUROC curve for
APACHE IV score was 0.404 (95%CI, 0.218–0.589); the opti-
mal cut-off score was 98 with a sensitivity of 78.6% and a
specificity of 100%.
4. Discussion
The risk stratification of severely ill patients remains problem-
atic, resulting in an increased interest in potential circulating
markers such as VEGF. Some studies have shown that serum
VEGF level is increased in polytrauma and severe sepsis [2,3].
In the current study there was no significant correlation
between VEGF level and age (P= 0.258) or sex
(P= 0.171). This finding is concurrent with the result of
Karlsson et al. [27] who demonstrated that neither age nor
sex correlated with VEGF level.
The VEGF1 and 2 levels were significantly higher in all
included septic patients when compared with the levels
detected in healthy controls (P= 0.001 and <0.001 respec-
tively). However, no significant differences were observed
between the VEGF1 and VEGF2 levels (P= 0.272).
Table 2 VEGF and severity of sepsis at ICU admission of patients entered into the study.
Severity of sepsis No. Mean (ng/l)±SD Min. Max. Med. P Value
VEGF 1
Sepsis 20 575 ± 212.94 280 870 480 *0.142
Severe sepsis 3 1043.33 ± 353.46 810 1450 870 **0.009
Septic shock 17 911.18 ± 449.86 400 1600 820 ***0.604
VEGF 2
Sepsis 15 787.12 ± 163.99 440 940 860 *0.917
Severe sepsis 3 700 ± 183.85 640 900 770 **0.588
Septic shock 11 863.65 ± 436.26 440 1660 830 ***0.641
* Significance between sepsis vs severe sepsis.
** Significance between sepsis vs septic shock.
*** Significance between severe sepsis vs septic shock.
Table 3 Correlation of VEGF(ng/l) and CRP(mg/l) and Microalbuminuria (mg/g) of patients entered into the study.
Biomarker No. Mean ± SD Minimum Maximum Median R P Value
VEGF 1 40 750.50 ± 380.34 280 1600 775 +0.475 *0.002
CRP 1 42.20 ± 22.96 12 96 38 ++0.623 ** < 0.001
Microalbuminuria 498.02 ± 285.32 44 872 495
VEGF 2 29 802.06 ± 292.65 440 1660 850 +++0.631 *** < 0.001
CRP 45.06 ± 22.66 22 96 48 ++++0.607 **** < 0.001
Microalbuminuria 53.56 ± 233.51 163 872 581
+ Correlation between VEGF 1 vs CRP 1.
++ Correlation between VEGF 1 vs microalbuminuria 1.
+++ Correlation between VEGF 2 vs CRP 2.
++++ Correlation between VEGF 2 vs microalbuminuria 2.
* Significance between VEGF 1 vs CRP 1.
** Significance between VEGF 1 vs microalbuminuria 1.
*** Significance between VEGF 2 vs CRP 2.
**** Significance between VEGF 2 vs microalbuminuria 2.
Table 4 Correlation of VEGF(ng/l) and APACHE IV and SOFA of patients entered into the study.
Biomarker No. Mean ± SD Minimum Maximum Median R P Value
VEGF 1 40 750.50 ± 380.34 280 1600 775 +0.397 *0.011
APACHE 1 87.53 ± 15.19 65 112 86 ++0.153 ** < 0.345
SOFA 1 9.65 ± 4.19 3 17 9.5
VEGF 2 29 802.06 ± 292.65 440 1660 850 +++0.410 ***<0.034
SOFA 3 12.58 ± 4.54 2 17 14 ++++0.291 **** < 0.133
+ Correlation between VEGF 1 vs APACHE 1.
++ Correlation between VEGF 1 vs SOFA 1.
+++ Correlation between VEGF 2 vs APACHE 1.
++++ Correlation between VEGF 2 vs SOFA 3.
* Significance between VEGF 1 vs APACHE 1.
** Significance between VEGF 1 vs SOFA 1.
*** Significance between VEGF 2 vs APACHE 1.
**** Significance between VEGF 2 vs SOFA 3.
Prognostic value of Vascular Endothelial Growth Factor in sepsis syndrome 123These results were similar to the results found by Karlsson
et al. [27], who reported that the median VEGF level in septic
patients on day 0 was 423 ng/l, which is higher than the median
VEGF level of healthy control (260 ng/l), P= 0.029. After72 h, VEGF levels were still higher in septic patients, with
median VEGF level of 521 ng/l versus healthy control
(P= 0.003). However, no significant correlation was found
between VEGF levels on day 0 and after 72 h.
Figure 1 ROC curve analysis of VGEF concentrations for
prediction of mortality.
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demonstrated that the patients who had been diagnosed with
sepsis or septic shock at admission to the ICU had significantly
higher levels of plasma VEGF than non-infected healthy con-
trol [132 ± 112 ng/l,166 ± 171 ng/l respectively versus 58
± 38 ng/l], (P< 0.01).
Regarding the severity of sepsis at ICU admission, the cur-
rent study demonstrated that the elevated levels of admission
VEGF in the studied septic patients increased with the increas-
ing severity of the septic condition at ICU admission to such
an extent that the patients with a diagnosis of septic shock
had significantly higher plasma admission VEGF levels than
those with sepsis, (P= 0.009); however, no significant relation
was found between the plasma admission VEGF levels in
patients with severe sepsis and those with sepsis or septic shock
(P= 0.142 and 0.604 respectively). This may be explained by
the small number of patients who had severe sepsis in the pre-
sent study.
Also, the circulating admission VEGF levels were signifi-
cantly higher in patients who needed organ supportive mea-
sures (MV, inotropic/vasopressor support and hemodialysis)
during their ICU stay (P= 0.002, 0.006 and 0.008
respectively).
In the current study, with increasing values of APACHE IV
scores reflecting the severity of sepsis and higher risk of mor-
tality, higher level of admission VEGF was observed
(r= 0.397, p< 0.001). Also, admission VEGF level was sig-
nificantly positively correlated with APACHE IV score
(r= 0.397, p< 0.001).
Though APACHE IV was used in this study, this observa-
tion goes with the results obtained by Nathan et al. [28] who
reported that with increasing values of APACHE II scores,
higher VEGF levels were observed. Also, this observation goes
with the results obtained by Liu et al. [29] who found that the
VEGF level showed obvious positive correlation with
APACHE II score (r= 0.510, P< 0.001).
However, there was no significant correlation between the
SOFA scoring system and the levels of admission VEGF and
VEGF 2 (r= 0.153 and 0.291 respectively); this observation
is in agreement with Yang et al. [30], who studied the predic-
tive value of the VEGF level for the disease severity and organ
dysfunction of patients with pneumonia-related sepsis, report-
ing that the role of the initial plasma VEGF level in predicting
organ dysfunction was insignificant.
Also, the current study demonstrated that admission
VEGF level was significantly correlated with CRP and
Microalbuminuria (r= 0.475 with p= 0.002 and 0.623 with
p< 0.001 respectively). In contrast, Basu et al. [31] reported
that no significant correlation was found between level of
microalbuminuria and serum VEGF-A in septic patients
(p= 0.396). Further larger studies are needed to study these
correlations in the septic patients.
In the current study, we demonstrated that ICU mortality
rate was 60%. The admission VEGF level in non survivors
was significantly higher than that in survivors (P= 0.001).
However, there was no significant difference between VEGF
2 level in non survivors and in survivors (P= 0.268).
In agreement with the current results, Flier et al. [32]
reported that maximum VEGF levels during severe sepsis were
higher in non survivors than in survivors (313 ± 53 ng/l vs.
147 ± 21 ng/l; P= 0.018). In contrast, Yang et al. [30],reported that there was no statistically significant difference
in the plasma VEGF levels between the survivors and non-
survivors of pneumonia-related septic shock (219.9
± 232.1 ng/l vs 386.5 ± 524.1 ng/l, P= 0.455); in addition,
Karlsson et al. [27] reported that the main finding of their
study was that although VEGF level is increased in severe sep-
sis, low VEGF level is associated with more severe forms of
organ dysfunction and mortality. These observations indicate
that the complex effect of VEGF in sepsis remains unclear.
ROC curve was calculated for the use of plasma VEGF
level as a predictor of ICU mortality. The AUROC curve
for plasma admission VEGF to predict ICU mortality was
0.746 (95% confidence interval, 0.594–.898, p= 0.009), with
an optimal cutoff value of 410 ng/l; this value resulted in a sen-
sitivity of 85.15% and a specificity of 92.3% for ICU mortality
(Fig 1).
In contrast with these results, Karlsson et al. [27] reported
that the ROC curve for hospital mortality at the time day 0
when the VEGF samples were taken showed an AUROC
curve of 0.58 (95% confidence limits 0.48–0.68, P= 0.1).
However, the ROC curve for hospital mortality and SOFA
score at the time day 0 when the VEGF samples were taken
showed AUROC curve of 0.73 (95% confidence limits 0.65–
0.82, P< 0.001) (see Fig. 2).
Limitation of the study: (1) The relatively small number of
cases may lead to a wide range of standard deviations of bio-
marker levels. (2) The samples were taken only at two time
points; therefore, the variation trend of this biomarker in the
course of sepsis could not be evaluated in the present study.
The half-life of VEGF has been reported to be short, (33.7
± 13 min) based on pharmacokinetic studies with recombi-
nant VEGF. Nonetheless, previous studies have shown
increased VEGF levels up to 29 days, indicating sustained
VEGF production in patients with severe sepsis. [33] (3) Our
VEGF levels were measured in serum samples. Plasma samples
have been preferred by some investigators because platelet-
mediated secretion of VEGF during the clotting process could
interfere with the results. [34,35] However, it has been shown
recently that VEGF levels were correlated between plasma
and serum in paired samples in otherwise healthy women hav-
ing controlled ovarian hyperstimulation. [36]
Figure 2 ROC curve analysis of CRP concentrations, Microalbuminuria levels, APACHE IV and SOFA scores for prediction of
mortality.
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Admission VEGF (measured by ELISA) may be used as a
rapid, simple and easy to perform and interpret test for the
early prognosis and prediction of adverse outcome of septic
patients at their ICU admission. It correlates with the severity
of septic condition, mortality and needs for mechanical venti-
lator, hemodynamic support and hemodialysis.
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